Monday's Small-cap Movers under Crystal Research's Coverage

Posted by Laura Swartz

August 6, 2012 at 5:04 PM

CNBC today published an article wherein the founder of Vanguard Group discussed his view on the necessity of investing in equities, which while higher risk, offer the potential for higher reward.

Read More

Topics: Crystal Research Associates, T3 Motion, Advaxis, Bioniche, Pluristem Therapeutics, Peregrine, Adamis

Healthcare Conferences and News: Week of 1/9 to 1/13

Posted by Karen Goldfarb

January 13, 2012 at 11:20 AM

This has been a big week for healthcare and biotech.

Read More

Topics: Crystal Research Associates, NVIV, GenSpera, OneMedForum, MedPro, biotech, Advaxis, Peregrine, Neuralstem, Leslie Ziegler, Gunnar Weikert, PPHM, General Cannabis, SearchCore

Recent Financial Results and Updates

Posted by Laura Swartz

February 14, 2011 at 9:50 AM

Last week, several companies within our coverage universe released financial results and corporate updates, including CEL-SCI Corporation (CVM-NYSE Amex), Pro-Pharmaceuticals Inc. (PRWP-OTC), and Advaxis Inc. (ADXS-OTC). In addition, Neuralstem, Inc. (CUR?-NYSE Amex)? announced a breakthrough in its clinical trials that it believes could greatly influence the treatment of amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease—a potentially fatal neuromuscular disorder.

Read More

Topics: Newsworthy Events, Advaxis, CEL-SCI, Multikine

Up to $1 Billion in New Credits/Grants for Healthcare

Posted by Laura Swartz

November 15, 2010 at 10:33 AM

As part of the Patient Protection and Affordable Care Act of 2010, Congress established a program known as the Qualifying Therapeutic Discovery Project (QTDP) to offer tax credits or grants for projects that show significant potential to produce new and cost-saving therapies, support jobs, and increase the U.S.’s competitiveness. Under the program, a total of $1 billion is allocated for credits and grants.

Read More

Topics: Newsworthy Events, Advaxis

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic